THE EFFECT OF ANX005, AN ANTI-C1Q ANTIBODY, ON BIOMARKERS OF TARGET AND PATHWAY ENGAGEMENT AND NEURODEGENERATION IN ALS PATIENTS

Annexon, Inc., South San Francisco CA

Investigators